Ipamorelin (2mg) 5 vials ^Sale

Ipamorelin is a pentapeptide and selective agonist of the ghrelin receptor (GHS-R1a) — the first selective growth-hormone secretagogue. It is studied for pulsatile GH release from pituitary somatotrophs with minimal effect on ACTH, cortisol, prolactin and other pituitary hormones. This product is supplied as a lyophilized research-grade peptide for in vitro and preclinical laboratory investigation only.

Investigational directions enabled by the published mechanism — not therapeutic claims.

• ◆Growth-hormone secretion: pulsatile GH release in muscle-growth and tissue-repair models
• ◆Selective activity: minimal cortisol, prolactin and ACTH effect — a cleaner profile than earlier GHRPs
• ◆Bone & muscle health: bone mineral content and longitudinal bone-growth models (sarcopenia/osteoporosis)
• ◆Recovery & GH/IGF-1 axis: healthy-aging, cachexia and post-injury recovery contexts

In published models, selective GHS-R1a agonism triggers pulsatile GH release from somatotrophs, amplifying physiological GH pulses rather than producing a tonic elevation. It shows no significant rise in ACTH/cortisol, prolactin, FSH, LH or TSH (>200× selectivity vs ACTH), and the resulting GH drives hepatic IGF-1 with anabolic and bone-remodeling signaling.

Key literature: Raun et al., 1998, Eur J Endocrinol · Gobburu et al., 1999 · Svensson et al., 2000 · Andersen et al., 2001.